- Home
- URG vs SVRA Comparison
URG vs SVRA Comparison
Compare URG & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URG
- SVRA
- Stock Information
- Founded
- URG 2004
- SVRA N/A
- Country
- URG United States
- SVRA United States
- Employees
- URG N/A
- SVRA N/A
- Industry
- URG Precious Metals
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- URG Basic Materials
- SVRA Health Care
- Exchange
- URG Nasdaq
- SVRA Nasdaq
- Market Cap
- URG 458.8M
- SVRA 540.6M
- IPO Year
- URG N/A
- SVRA N/A
- Fundamental
- Price
- URG $1.12
- SVRA $2.80
- Analyst Decision
- URG Strong Buy
- SVRA Buy
- Analyst Count
- URG 2
- SVRA 7
- Target Price
- URG $2.45
- SVRA $9.86
- AVG Volume (30 Days)
- URG 3.6M
- SVRA 966.0K
- Earning Date
- URG 03-05-2025
- SVRA 03-06-2025
- Dividend Yield
- URG N/A
- SVRA N/A
- EPS Growth
- URG N/A
- SVRA N/A
- EPS
- URG N/A
- SVRA N/A
- Revenue
- URG $16,494,000.00
- SVRA N/A
- Revenue This Year
- URG $86.92
- SVRA N/A
- Revenue Next Year
- URG $73.30
- SVRA N/A
- P/E Ratio
- URG N/A
- SVRA N/A
- Revenue Growth
- URG 34.78
- SVRA N/A
- 52 Week Low
- URG $0.96
- SVRA $2.60
- 52 Week High
- URG $2.01
- SVRA $5.70
- Technical
- Relative Strength Index (RSI)
- URG 42.34
- SVRA 39.71
- Support Level
- URG $1.08
- SVRA $2.60
- Resistance Level
- URG $1.19
- SVRA $3.14
- Average True Range (ATR)
- URG 0.06
- SVRA 0.17
- MACD
- URG -0.00
- SVRA -0.01
- Stochastic Oscillator
- URG 17.50
- SVRA 32.79
About URG Ur Energy Inc (Canada)
Ur-Energy Inc is y is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.